Business
NFL Biosciences Announces the Publication of the Results of Its Phase II Clinical Trial CESTO II Evaluating NFL-101 in Smoking Cessation in Nicotine & Tobacco Research, the Official Journal of the Society for Research on Nicotine and Tobacco (SRNT)
MONTPELLIER, France, September 01, 2025--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces the publication of the full results of its Phase 2 clinical trial CESTO II, conducted in 318 smokers. The scientific article, entitled "Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase 2 Clinical Trial CESTO2", has been published
About this update from Nfl Biosciences Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"The SRNT, the world’s leading scientific society dedicated to nicotine and tobacco research, publishes the results of the CESTO II study in its reference journal, thereby ensuring their optimal dissemination within the specialized scientific community","length":251,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Two administrations of NFL-101 at the 100 µg dose demonstrated a significant increase in continuous abstinence and a durable reduction in craving, the irresistible urge to smoke","length":177,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"NFL-101 shows an excellent safety profile, comparable to placebo","length":64,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":492,"olType":false},{"type":"text","content":"MONTPELLIER, France, September 01, 2025--(BUSINESS WIRE)--Regulatory News:","length":74,"tagName":"p"},{"type":"text","content":"NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces the publication of the full results of its Phase 2 clinical trial CESTO II, conducted in 318 smokers. The scientific article, entitled "Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase 2 Clinical Trial CESTO2", has been published in Nicotine & Tobacco Research — an international peer-reviewed reference journal, the official journal of the Society for Research on Nicotine and Tobacco (SRNT), and published by Oxford University Press. This publication reflects the recognition of the CESTO II results by the international scientific community and further enhances their global visibility.","length":815,"tagName":"p"},{"type":"text","content":"A global public health challenge","length":32,"tagName":"p"},{"type":"text","content":"Tobacco use remains the leading preventable cause of mortality worldwide, responsible for more than 8 million deaths every year according to the WHO. Despite strong quit intentions among most smokers, permanent success rates remain low. Current treatments require prolonged daily use and suffer from poor adherence, often due to the side effects associated with their administration. NFL-101 stands out with an optimized dosing regimen that promotes adherence with o...